Influenza A virus vaccine H5N1 - iBio

Drug Profile

Influenza A virus vaccine H5N1 - iBio

Alternative Names: HAI-05 Influenza Vaccine; Pandemic avian influenza vaccine - iBio; Plant virus derived influenza vaccine - iBio

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INB:Biotechnologies
  • Developer iBio Inc
  • Class Influenza A virus H5N1 vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(In volunteers) in USA (IM)
  • 30 Nov 2015 Phase I development is ongoing in USA
  • 30 Nov 2015 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top